Actively Recruiting
Open-Label Study of Cebranopadol for Moderate to Severe Acute Pain After Surgery or Musculoskeletal Injury
Led by Adneuris Therapeutics, Inc. · Updated on 2026-10-23
160
Participants Needed
15
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of cebranopadol in treating moderate to severe acute pain of surgical or non-surgical origin. This phase 3, open-label, single-arm study focuses on participants aged 18 to 75 years who experience acute pain from ambulatory surgery expected to last at least 72 hours or from traumatic or non-traumatic musculoskeletal conditions. Participants receive cebranopadol at a starting dose of 400 micrograms once daily for up to 14 days or until their pain resolves, whichever comes first. This study does not use a placebo or comparison group, and the treatment is administered openly without masking. During the study, participants will be monitored for pain intensity using the Sum of Pain Intensity Differences through 48 hours SPID48 as the primary outcome measure. They will also be evaluated for safety and tolerability over the treatment period. The study spans from September 2026 to February 2027, with ongoing assessments throughout the treatment duration.
CONDITIONS
Brief Title
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Research Team
S
Study Director, Adneuris Therapeutics
E
Emilio Quetglas, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here